Subscribe To
Why coherus biosciences stock soared today
Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for ...
October 30, 2023, 5:43 pm
Intuitive machines stock climbs on lunar mission plan as mcdonald's edges higher ahead of results
Coherus BioSciences stock CHRS, -3.65% rose 17% as the Food and Drug Administration approved its treatment for ...
October 30, 2023, 5:20 am
Global market for nasopharyngeal carcinoma treatment is expected to rise at a cagr of 5.9% to hit a revenue of us$ 2.1 billion | future market insights, inc.
The nasopharyngeal carcinoma treatment market includes various treatment options such as surgery, radia...
May 5, 2023, 1:30 am
Viracta therapeutics announces first clinical response in epstein-barr virus-positive (ebv+) solid tumor setting and outlines key 2023 clinical objectives
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) ...
January 8, 2023, 6:00 pm
Coherus and junshi biosciences share update on the fda review of the biologics license application (bla) for toripalimab as treatment for recurrent or metastatic nasopharyngeal carcinoma (npc)
– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA – – Coherus and Junshi B...
December 24, 2022, 5:01 am
Viracta therapeutics announces preliminary dose-ranging data from the phase 1b/2 trial of nana-val in advanced epstein-barr virus-positive (ebv+) solid tumors at the esmo immuno-oncology congress
Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal c...
November 30, 2022, 11:10 pm
Fda rejects junshi - coherus' toripalimab for rare head & neck cancer
The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab applic...
May 2, 2022, 9:25 am